Simon P Fricker

Summary

Affiliation: Genzyme Corporation
Country: USA

Publications

  1. ncbi Metal compounds for the treatment of parasitic diseases
    Simon P Fricker
    Genzyme Corporation, 49 New York Avenue, P O Box 9322, Framingham, MA 01701 9322, USA
    J Inorg Biochem 102:1839-45. 2008
  2. ncbi A novel CXCR4 antagonist for hematopoietic stem cell mobilization
    Simon P Fricker
    Genzyme Corp, Framingham, MA 01701 9322, USA
    Expert Opin Investig Drugs 17:1749-60. 2008
  3. ncbi Cysteine proteases as targets for metal-based drugs
    Simon P Fricker
    Genzyme Corp, 49 New York Ave, Framingham, MA 01701 9322, USA
    Metallomics 2:366-77. 2010
  4. ncbi Strategies for the biological evaluation of gold anticancer agents
    Simon P Fricker
    Genzyme Corp, Framingham, MA 01701, USA
    Anticancer Agents Med Chem 11:940-52. 2011
  5. ncbi CXCL12 (SDF-1)/CXCR4 pathway in cancer
    Beverly A Teicher
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Clin Cancer Res 16:2927-31. 2010
  6. ncbi Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approach
    Markus Metz
    Department of Medicinal Chemistry, Genzyme Corporation, 153 Second Avenue, Waltham, Massachusetts 02451, USA
    J Am Chem Soc 133:16477-85. 2011
  7. ncbi Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors
    Rebecca S Y Wong
    Genzyme Corporation, Cambridge, Massachusetts, USA
    Mol Pharmacol 74:1485-95. 2008

Collaborators

Detail Information

Publications7

  1. ncbi Metal compounds for the treatment of parasitic diseases
    Simon P Fricker
    Genzyme Corporation, 49 New York Avenue, P O Box 9322, Framingham, MA 01701 9322, USA
    J Inorg Biochem 102:1839-45. 2008
    ..In conclusion this preliminary data indicates that metal complexes targeted at parasite cysteine proteases show promise for the treatment of both Chagas' disease and leishmaniasis...
  2. ncbi A novel CXCR4 antagonist for hematopoietic stem cell mobilization
    Simon P Fricker
    Genzyme Corp, Framingham, MA 01701 9322, USA
    Expert Opin Investig Drugs 17:1749-60. 2008
    ..Current mobilization regimes frequently result in inadequate numbers of HSC for transplant therefore alternative methods of mobilization are required...
  3. ncbi Cysteine proteases as targets for metal-based drugs
    Simon P Fricker
    Genzyme Corp, 49 New York Ave, Framingham, MA 01701 9322, USA
    Metallomics 2:366-77. 2010
    ..These data are reviewed below and discussed in the context of possible therapeutic applications including cancer and parasitic disease...
  4. ncbi Strategies for the biological evaluation of gold anticancer agents
    Simon P Fricker
    Genzyme Corp, Framingham, MA 01701, USA
    Anticancer Agents Med Chem 11:940-52. 2011
    ..The importance of mechanistic studies which have led to the identification of new molecular targets for gold drugs, and in vivo evaluation are emphasized...
  5. ncbi CXCL12 (SDF-1)/CXCR4 pathway in cancer
    Beverly A Teicher
    Genzyme Corporation, Framingham, Massachusetts 01701 9322, USA
    Clin Cancer Res 16:2927-31. 2010
    ..The CXCL12/CXCR4 axis is involved in tumor progression, angiogenesis, metastasis, and survival. This pathway is a target for therapeutics that can block the CXCL12/CXCR4 interaction or inhibit downstream intracellular signaling...
  6. ncbi Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approach
    Markus Metz
    Department of Medicinal Chemistry, Genzyme Corporation, 153 Second Avenue, Waltham, Massachusetts 02451, USA
    J Am Chem Soc 133:16477-85. 2011
    ..The obtained mutant fingerprint profiles of CCR5 inhibitors were used to translate the CCR5 allosteric binding site into a general pharmacophore, which can be used for discovering new inhibitors...
  7. ncbi Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors
    Rebecca S Y Wong
    Genzyme Corporation, Cambridge, Massachusetts, USA
    Mol Pharmacol 74:1485-95. 2008
    ..These mechanistic studies might prove to be useful for the development of future generations of CXCR4 inhibitors with improved clinical pharmacology and safety profiles...